ALX ONCOLOGY HOLDINGS INC (ALXO) Form SCHEDULE 13D/A — Oct 16, 2026
venBio's investment vehicles and Corey Goodman filed Amendment No. 2 to their Schedule 13D on ALX Oncology, updating beneficial ownership after Fund I exchanged 253,826 common shares for a pre-funded warrant to purchase the same number of shares at $0.001 per share on October 14, 2026. Mr. Goodman, the group's key reporting person, is shown with 12,927,442 shares beneficially owned, or 9.99% of the class.
Key figures
- Shares Outstanding
- 0
- Fund1 shares
- 4307034
- Fund2 shares
- 8453038
- Fund1 percent
- 3.3%
- Fund2 percent
- 6.5%
- Goodman percent
- 9.99%
- Warrant blocker limit
- 9.99% (may be increased up to 19.99% on 61 days notice)
- Goodman aggregate shares
- 12927442
- Prefunded warrant shares
- 253826
- Shares surrendered for exchange
- 253826
- Prefunded warrant exercise price
- $0.001
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.